If you're holding XLV alongside other healthcare ETFs, consolidation might simplify your portfolio and reduce fees. But does it make sense for you? Here's the gist:
- Performance: XLV's 5-year return (+13.33%) lags behind peers like VHT (+18.21%) and FHLC (+18.13%). However, it outperformed some specialized ETFs over shorter periods.
- Fees: XLV has a low expense ratio (0.08%), on par with broad healthcare ETFs like VHT and FHLC.
- Overlap: XLV shares significant holdings with broad ETFs but differs from niche funds like IHI (medical devices) or PPH (pharmaceuticals).
- Pros of Consolidation: Lower fees, easier management, and reduced tax complexities.
- Cons of Consolidation: Loss of niche exposure and potential concentration risk.
Quick Comparison
| ETF | 1-Year Return | 3-Year Return | 5-Year Return | Expense Ratio | Focus Area |
|---|---|---|---|---|---|
| XLV | +2.50% | -2.04% | +13.33% | 0.08% | Broad U.S. healthcare |
| VHT | +2.65% | -5.52% | +18.21% | 0.10% | Broad healthcare |
| IHI | +8.61% | -19.72% | +24.17% | 0.39% | Medical devices |
| FHLC | +2.60% | -5.45% | +18.13% | 0.08% | Broad healthcare |
| PPH | +8.11% | +2.66% | +5.38% | 0.35% | Pharmaceuticals |
Bottom Line
Consolidating into XLV could streamline your portfolio and cut costs, especially if you own overlapping ETFs like VHT or FHLC. However, specialized ETFs like IHI or PPH offer targeted exposure that XLV lacks. Evaluate your goals, tax impacts, and risk tolerance before deciding.
XLV Overview and Key Metrics
Investment Approach and Sector Coverage
The Health Care Select Sector SPDR Fund (XLV) centers exclusively on the U.S. healthcare sector, managing a substantial $36.491 billion in net assets. This makes it one of the largest ETFs focused on healthcare. XLV offers broad exposure to American healthcare companies, encompassing pharmaceutical, biotechnology, medical device, and healthcare service firms. However, it doesn't break down its holdings by specific sub-industries. Historically, the healthcare sector has shown resilience during economic downturns and benefits from enduring trends like an aging population and increasing healthcare expenditures. Let’s take a closer look at how XLV performs compared to other healthcare ETFs.
Historical Performance and Risk Metrics
As of November 14, 2025, XLV delivered a year-to-date (YTD) return of +12.56%, with gains of +17.02% over the past 3 months. Its 1-year return stands at +2.50%, while its 3-year performance shows a slight decline of -2.04%. Over a 5-year period, XLV achieved a return of +13.33%, averaging about 2.5% annually. In a 1-year comparison, XLV underperformed against IHI (+8.61%) and PJP (+9.72%) but outpaced IBB (-2.40%) and IHF (-7.88%). On a 3-year scale, XLV has held up better than many specialized healthcare ETFs, which experienced sharper declines.
Expense Ratio and Dividend Yield
XLV boasts a low expense ratio of 0.08%, meaning an investor pays just $8 annually for every $10,000 invested. While specific dividend yield details aren't included in the data, healthcare ETFs often provide modest yields, thanks to the dividend-paying companies in their portfolios. With its low fees and broad sector coverage, XLV serves as a cost-efficient option for anchoring a healthcare allocation in an investment portfolio.
XLV vs Other Healthcare ETFs
Performance Comparison: 1/3/5-Year Returns and Risk
When comparing XLV's performance to other healthcare ETFs over different timeframes, there are some clear differences in returns. Here's a breakdown of 1-, 3-, and 5-year returns for XLV and its peers:
| ETF | Name | 1-Year Return | 3-Year Return | 5-Year Return |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR Fund | +2.50% | -2.04% | +13.33% |
| VHT | Vanguard Health Care Index Fund ETF | +2.65% | -5.52% | +18.21% |
| IHI | iShares U.S. Medical Devices ETF | +8.61% | -19.72% | +24.17% |
| IHF | iShares U.S. Healthcare Providers ETF | -7.88% | -7.09% | +17.64% |
| FHLC | Fidelity MSCI Health Care Index ETF | +2.60% | -5.45% | +18.13% |
| PPH | VanEck Pharmaceutical ETF | +8.11% | +2.66% | +5.38% |
Over the past year, XLV's return of +2.50% was surpassed by IHI (+8.61%) and PPH (+8.11%), while IHF struggled with a loss of –7.88%.
Looking at 3-year performance, XLV's decline of –2.04% was less severe than VHT (–5.52%), FHLC (–5.45%), and IHI (–19.72%). PPH stood out as the only ETF with positive growth (+2.66%) during this period.
Over the 5-year horizon, XLV achieved a +13.33% return, but this trailed behind VHT (+18.21%), FHLC (+18.13%), and IHI, which led the group with a return of +24.17%. However, IHI's higher returns come with greater volatility.
Next, let’s dive into the portfolio differences that drive these performance variations.
Sector and Holding Overlap Analysis
The overlap between XLV and other healthcare ETFs largely depends on their investment focus:
- VHT and FHLC: These ETFs track broader healthcare indices and have significant overlap with XLV, particularly in large-cap pharmaceutical, medical device, and healthcare service companies.
- IHI: This fund specializes in medical devices, holding companies like Medtronic, Abbott Laboratories, and Danaher. While XLV includes some of these names, IHI’s narrower focus creates a distinct portfolio.
- PPH: Concentrating on pharmaceutical companies, PPH differs from XLV's more diversified holdings by focusing exclusively on drug manufacturers.
- IHF: With its focus on hospital systems, insurance providers, and healthcare services, IHF offers minimal overlap with XLV, making it a more diversified option for investors looking beyond XLV's broader approach.
XLV provides a balanced exposure to the healthcare sector, while specialized ETFs like IHI and PPH offer more targeted investments. These differences in portfolio composition directly influence their performance and risk profiles.
5 Best Healthcare ETFs (XLV, VHT, + More)
sbb-itb-e429e5c
Should You Consolidate Your Healthcare ETFs?
After evaluating performance and overlaps, the next step is deciding whether consolidating into XLV aligns with your investment strategy. The right choice depends on your financial situation, goals, and tax considerations.
Benefits of Consolidation
Moving to a single healthcare ETF like XLV offers several advantages:
- Simplified management: Managing one fund is easier and less time-consuming than juggling multiple ETFs.
- Cost savings: Consolidating overlapping ETFs can cut down on duplicate fees while maintaining broad market exposure.
- Improved tax efficiency: Fewer holdings mean fewer dividend distributions and capital gains events, streamlining tax filing.
- Reduced wash sale risks: Overlapping positions can increase the likelihood of wash sale complications. A single ETF reduces this risk.
Drawbacks of Consolidation
Despite its benefits, consolidation has some downsides to consider:
- Loss of targeted exposure: Consolidating into XLV might limit access to niche areas within healthcare. XLV often focuses on large-cap companies, which could mean missing out on smaller, emerging firms with growth potential.
- Increased concentration risk: A single ETF may concentrate your portfolio in a few dominant names, reducing diversification.
- Timing matters: Different healthcare ETFs perform differently across market cycles. Specialized funds may offer better protection during volatility or unique opportunities in specific market conditions.
Tax Considerations and Mezzi's Tools
Tax implications play a critical role in the decision to consolidate. Here’s what to keep in mind:
- Capital gains impact: Selling appreciated positions can trigger taxes. Weigh the immediate tax hit against the long-term benefits of consolidation.
- Leverage Mezzi's wash sale tool: This tool helps monitor transactions across accounts, ensuring compliance and avoiding disallowed losses.
- Simplify tax-loss harvesting: Mezzi’s account aggregation and optimization tools make it easier to track cost basis and plan for future tax strategies.
Ultimately, the decision boils down to your priorities. Do you value the simplicity and cost efficiency of a single, broad exposure? Or do you prefer the flexibility and potential upside of maintaining specialized positions within the healthcare sector? Carefully weigh the trade-offs before making your move.
Conclusion
When comparing XLV and other broad healthcare ETFs, such as VHT and FHLC, the performance and fees are almost indistinguishable. All three maintain low expense ratios, ranging from 0.08% to 0.09%, while delivering similar returns over 1-, 3-, and 5-year periods. While VHT and FHLC have slightly outpaced XLV over the last five years, the difference is minimal. Given their overlapping portfolios and comparable fees, holding multiple broad healthcare ETFs often adds unnecessary complexity without offering meaningful benefits.
The significant overlap in holdings not only reduces genuine diversification but also introduces duplicate fee drag over time. For most investors, consolidating into a single broad healthcare ETF can streamline portfolio management and cut down on redundant costs, all while maintaining sufficient diversification.
That said, while consolidation simplifies things, specialized healthcare ETFs - like those focused on biotechnology (e.g., XBI, IBB, or ARKG) - present unique risk-return profiles. These funds come with higher expense ratios and increased volatility, making them suitable for investors looking for targeted exposure to specific healthcare subsectors. Depending on your investment strategy, a mix of broad and specialized ETFs might still be worth considering.
For those managing multiple overlapping ETFs, tools like Mezzi can make the process easier. Mezzi’s platform offers features like account aggregation and tax optimization, helping investors avoid wash sale issues during consolidation. Its X-Ray tool is particularly useful for identifying hidden overlaps in portfolios, ensuring more efficient decision-making. These tools align with the broader goal of balancing simplicity and diversification.
If your portfolio includes multiple broad healthcare ETFs with overlapping holdings, consolidating into one can reduce costs and simplify management. Keep your investment objectives in focus, evaluate the tax implications, and consider leveraging tools like Mezzi to optimize your exposure to the healthcare sector.
FAQs
What should I evaluate before consolidating my healthcare ETFs into XLV?
When considering whether to merge your healthcare ETFs into XLV, there are a few critical aspects to examine:
- Performance: Take a close look at XLV's total returns over 1, 3, and 5 years. Compare these figures against the performance of your current healthcare ETFs to get a sense of how it has historically stacked up.
- Overlap: Analyze the sectors and individual holdings in XLV versus your existing ETFs. This helps ensure your portfolio stays diversified and avoids holding the same stocks unnecessarily.
- Fees: Review the expense ratios. Consolidating into XLV might reduce your overall investment costs, which could improve your portfolio's cost efficiency.
By weighing these factors, you’ll be better equipped to decide if moving into XLV aligns with your financial strategy and streamlines your investments.
How does the overlap between XLV and other healthcare ETFs affect diversification and risk in my portfolio?
When XLV shares overlap significantly with other healthcare ETFs in your portfolio, it can limit diversification. Why? Because when multiple funds hold similar stocks, their performance tends to move in sync, reducing the variety in your investments.
This lack of diversification can heighten risk, particularly during downturns that affect the healthcare sector. A concentrated portfolio means you're more exposed to the ups and downs of specific companies or industries. To address this, take a closer look at how much overlap exists and assess whether it aligns with your overall investment strategy.
What tax considerations should I be aware of when consolidating my healthcare ETFs, and how can I manage them effectively?
When consolidating healthcare ETFs, keep in mind the potential impact of capital gains taxes if you're selling shares at a profit. If you've held the ETF for less than a year, your gains will generally be taxed at your regular income tax rate. However, if you've held it for over a year, you might qualify for the lower long-term capital gains tax rate. On the flip side, selling at a loss could provide an opportunity to offset other taxable gains through tax-loss harvesting.
To navigate these tax considerations, it’s a good idea to consult a tax professional. They can help you develop strategies like timing your sales to reduce the tax burden or leveraging tax-advantaged accounts such as IRAs. Above all, ensure that your consolidation efforts align with your broader financial goals and match your risk tolerance.
Related Blog Posts
- How do VPU and XLU compare on dividend yield, dividend growth, fees, and sector concentration?
- VXUS vs VEA+VWO: 5-year total return and overlap analysis (country/sector/holding overlap).
- VPU vs XLU (utilities): 5-year total return, dividend yield/growth, sector tilt differences.
- Health Care sector: which stocks/ETFs add diversification without duplicating my existing exposure?
Table of Contents
Book Free Consultation
Walk through Mezzi with our team, review your current situation, and ask any questions you may have.